Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells.

Authors :: Zhang P
Chen Z
Ning K
Jin J
Han X
Source :: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2017 Aug 26; Vol. 490 (3), pp. 1132-1138. Date of Electronic Publication: 2017 Jul 01.
Publication Year :: 2017
Abstract: B7-H3, an immunoregulatory protein, has been found highly expressed in several cancer types, and involved in cancer cell migration and invasion. Here, we investigated the role of B7-H3 in oxaliplatin resistance in colorectal cancer (CRC) cells. Transient silencing of B7-H3 enhanced oxaliplatin sensitivity by increasing oxaliplatin-induced DNA damage. The overexpression of B7-H3 increased oxaliplatin resistance reducing the formation of phosphorylated histone H2AX (γH2AX) loci. The silencing of X-ray repair cross complementing group 1 (XRCC1), upregulated in B7-H3 overexpressing cells, induced an increase in cell death following oxaliplatin treatment. Finally, the upregulation of XRCC1 expression induced by B7-H3 involved PI3K-AKT pathway. In conclusion, B7-H3 promotes the oxaliplatin resistance in CRC cells upregulating the expression of XRCC1 via PI3K-AKT pathway.<br /> (Copyright © 2017. Published by Elsevier Inc.)

Full Text Access

Tools